mTOR dysregulation and tuberous sclerosis-related epilepsy

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway is vital for neural network development.
• Deregulation of mTOR signaling is implicated in epileptogenesis, particularly in developmental pathologies like tuberous sclerosis complex (TSC).
• Mutations in mTOR pathway genes contribute to 'mTORopathies', a spectrum of neurological disorders.

Purpose of the Study:

• To investigate the role of mTOR signaling in epileptogenesis.
• To evaluate the efficacy and safety of mTOR inhibition as a therapeutic strategy for drug-resistant epilepsy in TSC.
• To determine the optimal dosage of mTOR inhibitors for reducing seizure frequency and severity.

Main Methods:

• Review of existing literature on mTOR signaling in epilepsy and developmental pathologies.
• Analysis of data from a double-blind, phase III randomized clinical trial (EXIST-3) in patients with TSC-related epilepsy.
• Evaluation of seizure reduction, safety, and tolerability of adjunctive mTOR inhibition therapy.

Main Results:

• mTOR signaling dysregulation is a common pathogenic mechanism in malformations of cortical development associated with epilepsy, autism, and intellectual disability.
• Adjunctive treatment with mTOR inhibition demonstrated efficacy and safety in reducing focal drug-resistant seizures in TSC epilepsy.
• The EXIST-3 trial provided insights into optimal mTOR inhibitor dosage, showing increased chances of seizure reduction with similar adverse events compared to lower doses.

Conclusions:

• mTOR pathway dysregulation is a shared mechanism in specific neurodevelopmental disorders with epilepsy.
• mTOR inhibition represents a promising therapeutic target for drug-resistant epilepsy in TSC.
• Optimized mTOR inhibition therapy offers a viable option for managing seizures in TSC patients.